Navigation Links
ACGT Surpasses $25 Million Funding Milestone with Two New Grants
Date:3/16/2015

Stamford, CT (PRWEB) March 16, 2015

Alliance for Cancer Gene Therapy (ACGT) — the nation’s only nonprofit dedicated exclusively to cell and gene therapies for cancer — has achieved a major milestone, surpassing $25 million donated to innovative and breakthrough cancer research. ACGT was founded by Barbara Netter and her late husband, Edward, in 2001 with the goal of transforming cancer into a manageable, treatable disease.

Pushing the foundation across the $25 million threshold are a pair of three-year, $250,000 grants to two esteemed scientists: Meenakshi Hegde, MD, of Texas Children’s Cancer Center at Baylor College of Medicine in Houston, TX, and Christopher Jewell, PhD, at University of Maryland, College Park. Dr. Hegde’s work will focus on immunotherapy, specifically adoptive cellular therapy for melanoma. Dr. Jewell’s research is centered on harnessing intra-lymph node gene therapy to promote tumor immunity. The grantees will develop genetically-modified T cells and cancer vaccines with the potential to stop cancer in its tracks.

“Drs. Hegde and Jewell are two outstanding scientists in the vanguard of treating and defeating cancer,” said Barbara Netter, ACGT’s President. “Their work offers tremendous hope to those battling cancer, and also to their loved ones.”

ACGT grants are awarded to promising researchers whose work dovetails with the foundation’s mission: Leveraging cell and gene therapies to supplant the more harrowing cancer treatments like radiation, chemotherapy and surgery. ACGT’s $25 million in grants have funded watershed research and trials such as those that activate patients’ own immune systems to battle cancer cells. These trials have saved the lives of cancer patients otherwise believed to be beyond treatment.

The two most recent grants continue ACGT’s mission of equipping innovative scientists with the tools and support to revolutionize the fight against cancer. ACGT grants range from $250,000 to $1 million, and reward both young, promising researchers and their more established colleagues. Past recipients include such pre-eminent scientists as University of Pennsylvania’s Dr. Carl June and Memorial Sloan-Kettering’s Dr. Michel Sadelain; this past summer, the Food and Drug Administration (FDA) granted “breakthrough” status to immunotherapy treatments for leukemia developed by each of these scientists for which ACGT provided early funding.

About Alliance for Cancer Gene Therapy (ACGT)
Established in 2001, ACGT (http://www.acgtfoundation.org) is the nation’s only not-for-profit dedicated exclusively to cell and gene therapy treatments for all types of cancer. One-hundred percent of contributions go directly to research. ACGT has funded 46 grants in the U.S. and Canada since its founding in 2001 by Barbara Netter, President, and her late husband, Edward, to conduct and accelerate critically needed innovative research. Since its inception, ACGT has awarded 31 grants to Young Investigators and 15 grants to Clinical Investigators, totaling more than $25 million in funding. ACGT is located at 96 Cummings Point Road, Stamford, CT 06902.

ACGT on Facebook: http://www.facebook.com/ACGTfoundation
ACGT on Twitter: http://www.twitter.com/ACGTfoundation
ACGT on YouTube: http://www.youtube.com/user/ACGTfoundation

Read the full story at http://www.prweb.com/releases/2015/03/prweb12585806.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. French Man Surpasses Two Years of Support with SynCardia Total Artificial Heart
2. SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
3. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
4. Magnetic Resonance Imaging Systems Market Is Expected to Reach $6,802.7 Million by 2020 - New Report by MarketsandMarkets
5. The North America Polycarbonate Market (2013–2019) is Estimated to Reach $2474.0 Million by 2019 - A Report by MicroMarket Monitor
6. New Patient Safety Study Reveals Misdiagnosis of 1 in Every 200 Prostate Biopsy Patients, Wasting Over $880 Million in Unnecessary Healthcare Expenditures Annually
7. The Middle East & Africa IR Detector Market is Estimated to Reach $23.9 Million by 2019 – A Report by MicroMarket Monitor
8. One Million Solutions in Health™ Announces its Launch as a Non-Profit Geared towards Life Sciences and Healthcare Scientific Advances – and Sharing Solutions Worldwide
9. The Europe Phosphatic Fertilizer Market is Estimated to Reach $5,654.27 Million by 2019 – A Report by MicroMarket Monitor
10. BIOREM announces orders for $3.7 million.
11. Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2019)... ... September 20, 2019 , ... ... Neurotrophic Factor (BDNF) testing in serum . BDNF plays a vital role in ... growth and differentiation of new neurons in the brain involved in learning, memory, ...
(Date:9/17/2019)... ... September 17, 2019 , ... Jennifer Hermansky and ... have been named to Law360’s 2019 Rising Stars. Hermansky and Xie, named an Immigration ... from 1,300 submissions, spanning 39 practice areas. The list highlights attorneys “whose legal accomplishments ...
(Date:9/11/2019)... ... September 09, 2019 , ... Tunnell Consulting, ... agencies, announced that its president and CEO Maryann Gallivan has been accepted into ... The Forbes Council accepted Gallivan based on the role she and Tunnell ...
(Date:9/9/2019)... , ... September 09, 2019 , ... Visikol CEO Dr. ... that was focused on how best to characterize 3D cell culture models. The inherent ... they are too thick and opaque to image through and therefore traditional wide-field or ...
Breaking Biology Technology:
(Date:10/3/2019)... ... October 02, 2019 , ... Connecticut Innovations ... ongoing support for Connecticut’s innovative, growing companies, today announced that it has closed ... payments and winner of the 2018 VentureClash competition. , The ...
(Date:9/30/2019)... FREDERICK, Md. (PRWEB) , ... ... ... a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal ... Australia for novel product formulations related to “Ready-to-Print” (RTP) cellular product formats ...
(Date:9/25/2019)... (PRWEB) , ... September 25, 2019 , ... ... biopharma leaders through off-the-record collaboration and dialogue, today announces its inaugural South ... Orleans BioInnovation Center in Louisiana. , Co-produced by Tulane University, this invitation-only ...
Breaking Biology News(10 mins):